SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Neuland Laboratories - Quaterly Results

10 May 2022 Evaluate
The Total revenue for the quarter ended March 2022 of  Rs. 2558.73 millions remain, more or less, the same.The company has announced a 26.69% increase in its profits to Rs . 218.27  millions for the  quarter ended March 2022 compared to Rs. 172.28 millions in the corresponding quarter in the previous year.A decline of 393.44 millions was observed in the OP in the quarter ended March 2022 from 400.35 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 2558.73 2447.05 4.56 9510.77 9369.13 1.51 9510.77 9369.13 1.51
Other Income 6.31 145.96 -95.68 20.77 160.95 -87.10 20.77 160.95 -87.10
PBIDT 393.44 400.35 -1.73 1442.70 1625.38 -11.24 1442.70 1625.38 -11.24
Interest 27.70 45.78 -39.49 134.94 178.98 -24.61 134.94 178.98 -24.61
PBDT 365.74 354.57 3.15 1307.76 1446.40 -9.59 1307.76 1446.40 -9.59
Depreciation 124.52 111.41 11.77 490.36 396.78 23.58 490.36 396.78 23.58
PBT 241.22 243.16 -0.80 817.40 1049.62 -22.12 817.40 1049.62 -22.12
TAX 22.95 70.88 -67.62 182.06 246.67 -26.19 182.06 246.67 -26.19
Deferred Tax -47.35 23.87 -298.37 -22.16 121.84 -118.19 -22.16 121.84 -118.19
PAT 218.27 172.28 26.69 635.34 802.95 -20.87 635.34 802.95 -20.87
Equity 129.00 129.00 0.00 129.00 129.00 0.00 129.00 129.00 0.00
PBIDTM(%) 15.38 16.36 -6.02 15.17 17.35 -12.56 15.17 17.35 -12.56

Neuland Laboratories Share Price

19089.60 91.75 (0.48%)
15-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1952.45
Dr. Reddys Labs. 1229.80
Cipla 1437.95
Zydus Lifesciences 1154.40
Lupin 2491.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: